These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 419159)

  • 1. Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway.
    Schneck DW; Sprouse JS; Shiroff RA; Vary JE; DeWitt FO; Hayes AH
    Pharmacology; 1979; 18(1):34-41. PubMed ID: 419159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.
    Gibson TP; Matusik J; Matusik E; Nelson HA; Wilkinson J; Briggs WA
    Clin Pharmacol Ther; 1975 Apr; 17(4):395-9. PubMed ID: 1122681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of isoniazid and other drugs on the acetylation of procainamide in the intact rat.
    Sprouse JS; Schneck DW; Hayes AH
    J Pharmacol Exp Ther; 1978 Dec; 207(3):698-704. PubMed ID: 731425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
    Horai Y; Ishizaki T; Sasaki T; Koya G; Matsuyama K; Iguchi S
    Br J Clin Pharmacol; 1982 Mar; 13(3):361-74. PubMed ID: 7059436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the acetylation of procainamide and sulfadimidine in man.
    Frislid K; Berg M; Hansteen V; Lunde PK
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):433-8. PubMed ID: 971707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoniazid acetylation phenotyping in Saudi Arabs.
    Matar KM; Mayet AY; Ayoola EA; Bawazir SA; Al-Faleh FZ; Al-Wazzan A
    J Clin Pharm Ther; 2004 Oct; 29(5):443-7. PubMed ID: 15482388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antinuclear antibodies during procainamide treatment and drug acetylation.
    Davies DM; Beedie MA; Rawlins MD
    Br Med J; 1975 Sep; 3(5985):682-4. PubMed ID: 52382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.
    Zysset T; Peretti E
    Eur J Clin Pharmacol; 1986; 30(4):463-6. PubMed ID: 3743623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus.
    Ishizaki T; Horai Y; Koya G; Matsuyama K; Iguchi S
    Arthritis Rheum; 1981 Oct; 24(10):1245-54. PubMed ID: 7306226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single sample saliva test to determine acetylator phenotype.
    Hutchings AD; Routledge PA
    Br J Clin Pharmacol; 1996 Nov; 42(5):635-7. PubMed ID: 8951197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
    Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA
    N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the metabolism of procainamide and sulfamethazine.
    Giardina E-GV ; Stein RM; Bigger JT
    Circulation; 1977 Feb; 55(2):388-94. PubMed ID: 832354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].
    Gawrońska-Szklarz B; Górnik W; Kutrzeba J; Wójcicki J; Zakrzewski J
    Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):921-3. PubMed ID: 1284448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capacity-limited elimination of procainamide in man.
    Tilstone WJ; Lawson DH
    Res Commun Chem Pathol Pharmacol; 1978 Aug; 21(2):343-6. PubMed ID: 694230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.